Therapy Areas: Diabetes
Boheringer and Lilly present initial results of empagliflozin compared with DPP-4 inhibitors study at ACC.19 and AMCP 2019
29 March 2019 -

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced initial results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world evidence study that show that empagliflozin is associated with a 22% relative risk reduction in all-cause hospitalisations, compared to DPP-4 inhibitors, within a mean follow-up of 5.4 months, it was reported yesterday.

Of those admitted to hospital, patients treated with empagliflozin were discharged earlier compared to those treated with DPP-4 inhibitors (17,539 matched pairs in each treatment group). Results also show that empagliflozin is associated with significantly fewer recurrent emergency department visits and physician's office visits compared to DPP-4 inhibitors. These initial results, observed during the first two years of the EMPRISE real-world evidence study evaluating US-only data, were presented at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 in San Diego, US.

Dr Mehdi Najafzadeh, PhD, MSc, MA, of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and instructor in Medicine, Harvard Medical School and study co-investigator, said 'People with diabetes are more likely to be admitted to hospital from any cause than those without the condition, experiencing longer and more costly hospital stays. This can have a substantial impact on healthcare resources. Initial results from the EMPRISE real-world study show that empagliflozin is associated with a relative risk reduction in hospitalisations and with a shorter length of hospital stay for people with type 2 diabetes.'

Login
Username:

Password: